[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].
Identifieur interne : 001C49 ( Ncbi/Merge ); précédent : 001C48; suivant : 001C50[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].
Auteurs : A. Guillard ; C. Chastang ; G. FenelonSource :
- Revue neurologique [ 0035-3787 ] ; 1986.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Levodopa.
- diagnosis : Parkinson Disease.
- mortality : Parkinson Disease.
- therapy : Parkinson Disease.
- Follow-Up Studies, Humans, Prognosis.
Abstract
As L-Dopa was marketed in France in 1971 for treatment of Parkinson's disease we used 1971 to divide a sample of patients into 2 groups. Group 1 (152 patients) includes patients with diagnosis made before 1971 and group 2 (264 patients) with diagnosis after 1971. The prognostic factors were motor deterioration, intellectual deterioration and death. The prognostic variables include the neuro-psychological status at the onset of the disease and at the beginning of L-Dopa treatment. The statistical analysis is based on Kaplan-Meier estimate, Log-rank test and Cox's model. In group 2, 10 years after the beginning treatment of L-Dopa, motor deterioration affected 60 p. 100 of the patients. The poor variables were akineto-hypertonic type, severe akinesia, poor clinical result after one year. Intellectual deterioration was frequent: 30 p. 100 at 10 years. The poor variables were age over 60, depression or psychotic episodes occurring during the first year. The 10 years-survival rate was 64 p. 100 and was not different from that recorded in a French population of same age and sex distribution. The poor variables were severe akinesia, presence of a Babinski sign, poor therapeutic result after one year, occurrence of psychotic episodes during the first year. The interval between the onset of the disease and the beginning of L-Dopa did not have any prognostic value, whatever the response criterion. In group 1, the same prognostic factors were pointed out. Survival and intellectual deterioration were not different in the 2 groups, but in group 1, motor deterioration appeared earlier.(ABSTRACT TRUNCATED AT 250 WORDS)
PubMed: 3797924
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001883
- to stream PubMed, to step Curation: 001842
- to stream PubMed, to step Checkpoint: 001842
Links to Exploration step
pubmed:3797924Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].</title>
<author><name sortKey="Guillard, A" sort="Guillard, A" uniqKey="Guillard A" first="A" last="Guillard">A. Guillard</name>
</author>
<author><name sortKey="Chastang, C" sort="Chastang, C" uniqKey="Chastang C" first="C" last="Chastang">C. Chastang</name>
</author>
<author><name sortKey="Fenelon, G" sort="Fenelon, G" uniqKey="Fenelon G" first="G" last="Fenelon">G. Fenelon</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1986">1986</date>
<idno type="RBID">pubmed:3797924</idno>
<idno type="pmid">3797924</idno>
<idno type="wicri:Area/PubMed/Corpus">001883</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001883</idno>
<idno type="wicri:Area/PubMed/Curation">001842</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001842</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001842</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001842</idno>
<idno type="wicri:Area/Ncbi/Merge">001C49</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].</title>
<author><name sortKey="Guillard, A" sort="Guillard, A" uniqKey="Guillard A" first="A" last="Guillard">A. Guillard</name>
</author>
<author><name sortKey="Chastang, C" sort="Chastang, C" uniqKey="Chastang C" first="C" last="Chastang">C. Chastang</name>
</author>
<author><name sortKey="Fenelon, G" sort="Fenelon, G" uniqKey="Fenelon G" first="G" last="Fenelon">G. Fenelon</name>
</author>
</analytic>
<series><title level="j">Revue neurologique</title>
<idno type="ISSN">0035-3787</idno>
<imprint><date when="1986" type="published">1986</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Follow-Up Studies</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (mortality)</term>
<term>Parkinson Disease (therapy)</term>
<term>Prognosis</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Follow-Up Studies</term>
<term>Humans</term>
<term>Prognosis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">As L-Dopa was marketed in France in 1971 for treatment of Parkinson's disease we used 1971 to divide a sample of patients into 2 groups. Group 1 (152 patients) includes patients with diagnosis made before 1971 and group 2 (264 patients) with diagnosis after 1971. The prognostic factors were motor deterioration, intellectual deterioration and death. The prognostic variables include the neuro-psychological status at the onset of the disease and at the beginning of L-Dopa treatment. The statistical analysis is based on Kaplan-Meier estimate, Log-rank test and Cox's model. In group 2, 10 years after the beginning treatment of L-Dopa, motor deterioration affected 60 p. 100 of the patients. The poor variables were akineto-hypertonic type, severe akinesia, poor clinical result after one year. Intellectual deterioration was frequent: 30 p. 100 at 10 years. The poor variables were age over 60, depression or psychotic episodes occurring during the first year. The 10 years-survival rate was 64 p. 100 and was not different from that recorded in a French population of same age and sex distribution. The poor variables were severe akinesia, presence of a Babinski sign, poor therapeutic result after one year, occurrence of psychotic episodes during the first year. The interval between the onset of the disease and the beginning of L-Dopa did not have any prognostic value, whatever the response criterion. In group 1, the same prognostic factors were pointed out. Survival and intellectual deterioration were not different in the 2 groups, but in group 1, motor deterioration appeared earlier.(ABSTRACT TRUNCATED AT 250 WORDS)</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3797924</PMID>
<DateCreated><Year>1987</Year>
<Month>02</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>1987</Year>
<Month>02</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN>
<JournalIssue CitedMedium="Print"><Volume>142</Volume>
<Issue>3</Issue>
<PubDate><Year>1986</Year>
</PubDate>
</JournalIssue>
<Title>Revue neurologique</Title>
<ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation>
</Journal>
<ArticleTitle>[Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].</ArticleTitle>
<Pagination><MedlinePgn>207-14</MedlinePgn>
</Pagination>
<Abstract><AbstractText>As L-Dopa was marketed in France in 1971 for treatment of Parkinson's disease we used 1971 to divide a sample of patients into 2 groups. Group 1 (152 patients) includes patients with diagnosis made before 1971 and group 2 (264 patients) with diagnosis after 1971. The prognostic factors were motor deterioration, intellectual deterioration and death. The prognostic variables include the neuro-psychological status at the onset of the disease and at the beginning of L-Dopa treatment. The statistical analysis is based on Kaplan-Meier estimate, Log-rank test and Cox's model. In group 2, 10 years after the beginning treatment of L-Dopa, motor deterioration affected 60 p. 100 of the patients. The poor variables were akineto-hypertonic type, severe akinesia, poor clinical result after one year. Intellectual deterioration was frequent: 30 p. 100 at 10 years. The poor variables were age over 60, depression or psychotic episodes occurring during the first year. The 10 years-survival rate was 64 p. 100 and was not different from that recorded in a French population of same age and sex distribution. The poor variables were severe akinesia, presence of a Babinski sign, poor therapeutic result after one year, occurrence of psychotic episodes during the first year. The interval between the onset of the disease and the beginning of L-Dopa did not have any prognostic value, whatever the response criterion. In group 1, the same prognostic factors were pointed out. Survival and intellectual deterioration were not different in the 2 groups, but in group 1, motor deterioration appeared earlier.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guillard</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chastang</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fenelon</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>fre</Language>
<PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<VernacularTitle>Etude à long terme de 416 cas de maladie de Parkinson. Facteurs de pronostic et implications thérapeutiques.</VernacularTitle>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Rev Neurol (Paris)</MedlineTA>
<NlmUniqueID>2984779R</NlmUniqueID>
<ISSNLinking>0035-3787</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1986</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1986</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">3797924</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Chastang, C" sort="Chastang, C" uniqKey="Chastang C" first="C" last="Chastang">C. Chastang</name>
<name sortKey="Fenelon, G" sort="Fenelon, G" uniqKey="Fenelon G" first="G" last="Fenelon">G. Fenelon</name>
<name sortKey="Guillard, A" sort="Guillard, A" uniqKey="Guillard A" first="A" last="Guillard">A. Guillard</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001C49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:3797924 |texte= [Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications]. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:3797924" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |